This site is intended for health professionals only
Saturday 15 December 2018
Share |

Topic: nice

November 8, 2018
Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ratio of daunorubicin and cytarabine

Jazz Pharmaceuticals plc has announced that the National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion for routine use on the National Health Service (NHS) in England and Wales.

Vyxeos is recommended for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)1 – two types of secondary AML.

July 10, 2018
In draft guidance published on 9 July NICE recommended that healthcare professionals prescribe antibiotics to people with COPD only when suffering from severe acute exacerbations

Antibiotics should be restricted when used for chronic obstructive pulmonary disease (COPD), the National Institute for Health and Care and Excellence (NICE) has urged.
 

June 6, 2018
Evidence on whether cabozantinib increases the overall length of time people live is “less certain” says the National Institute for Health and Care Excellence

The National Institute for Health and Care Excellence (NICE) has issued draft guidance rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.
 
Cabometyx (cabozantinib) is a treatment for adult patients with advanced renal cell carcinoma (RCC) following prior vascular endothelial growth factor (VEGF)-targeted therapy.
 
This month, [June] NICE said Cabozantinib was not recommended, within its marketing authorisation, for adults with untreated advanced renal cell carcinoma that is intermediate or poor risk.

May 17, 2018
NICE U-turn recommends Biogen’s Avonex® (interferon beta-1a) for relapsing-remitting multiple sclerosis

The National Institute for Health and Care Excellence (NICE) has recommended global biotechnology  company Biogen’s Avonex® (interferon beta-1a) as an option for treating relapsing-remitting multiple sclerosis.

The reappraisal of the treatment comes after the landmark Risk Sharing Scheme ended, at which point NICE began an appraisal of treatments including interferon beta-1a, Extavia (interferon beta-1b), glatiramer acetate and Betaferon (interferon beta-1b).

May 4, 2018
The NICE decision will result in quicker access for patients to the first selective IL-23 inhibitor

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the UK’s National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Determination (FAD) recommending Tremfya® (guselkumab) for treatment of adults with moderate to severe plaque psoriasis.1
 
The NICE recommendation states that guselkumab is recommended as an option for treating plaque psoriasis in adults, only if:

March 3, 2018
Welcome news for patients in England, Wales and Northern Ireland as avelumab is recommended for routine NHS use in previously treated metastatic Merkel Cell Carcinoma (mMCC) patients and for use in England within the Cancer Drugs Fund for those with previously untreated mMCC

The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) that recommends avelumab for treating adults with metastatic Merkel Cell Carcinoma (mMCC).1

February 16, 2018
NICE recommends NHS-wide prescribing of Ipsen’s cabozantinib for patients with medullary thyroid cancer

Ipsen has announced that adult patients in England and Wales with medullary thyroid cancer (MTC) could now benefit from treatment with Cometriq® (cabozantinib).

February 15, 2018
Positive NICE recommendation ensures access to Eisai's lenvatinib for subset of patients with very limited options

Eisai Europe Limited has announced that the National Institute for Health and Care Excellence (NICE) issued its final appraisal decision (FAD) recommending reimbursement of Lenvima® (lenvatinib) for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine (RAI-R DTC).1

January 19, 2018
Managed access agreement to be developed in parallel to urgently provide effective new treatment to patients in England

The National Institute for Health and Care Excellence (NICE) has formally invited Biogen to submit Spinraza (nusinersen), the first and only disease-modifying treatment for 5q spinal muscular atrophy (SMA), for assessment via the Single Technology Appraisal (STA) route.

November 9, 2017
NICE also recommends use of Merck’s multiple sclerosis therapy cladribine (Mavenclad®) for highly active disease in adults

NHS England has entered into a commercial agreement that allows NHS patients in England immediate access to the innovative new multiple sclerosis (MS) treatment, cladribine tablets (Mavenclad®).1

August 24, 2017
Ribociclib in combination with an aromatase inhibitor is a new and effective treatment option offering postmenopausal women with the most common form of advanced breast cancer the possibility of two years without disease progression

Novartis has announced that Kisqali®(ribociclib) has received authorisation from the European Commission for the treatment of advanced breast cancer. Ribociclib is now licensed for use in Europe as a first-line treatment in combination with an aromatase inhibitor in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer.

July 21, 2017
Humanised IL-5 antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment

Teva Pharmaceutical Industries Ltd has announced that the National Institute for Health and Care Excellence (NICE) in England has recommended Cinqaero® (reslizumab) in its Final Appraisal Determination (FAD).

July 13, 2017
NICE endorses prescribing across the NHS of Ipsen’s tablet cabozantinib, offering a new therapy option to help battle cancer resistance in advanced renal cell carcinoma in adults (after VEGF-targeted therapy)

The UK affiliate of Ipsen has announced that eligible patients with advanced kidney cancer could now benefit from treatment with Ipsen’s innovative therapy Cabometyx® (cabozantinib) via the NHS in England and Wales, following recommendation for use by NICE in their Final Appraisal Determination (FAD).

May 31, 2017
National Institute for Health and Care Excellence (NICE) recommendation helps fulfil unmet need for rare cancer patients by recommending access to targeted therapy

Novartis has announced that NICE has recommended Afinitor® (everolimus) in its final draft guidance for the treatment of well- or moderately-differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease.

December 1, 2016
Positive NICE recommendation means patients with severe refractory eosinophilic asthma in England and Wales can now have access to the biologic, mepolizumab

The National Institute for Health and Care Excellence (NICE) has today announced a positive recommendation for GSK’s Nucala®(mepolizumab) for use in a sub-group of adults with severe refractory eosinophilic asthma in England and Wales.1

September 2, 2016
NICE has recommended Xofigo® (radium-223 dichloride) in their draft guidance for treating hormone-relapsed prostate cancer with bone metastases to include men in whom docetaxel is contraindicated or not suitable

The National Institute for Health and Care Excellence (NICE) has recommended Xofigo® (radium-223 dichloride) in their draft guidance for adult men with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases where docetaxel is contraindicated or is not suitable.1

August 19, 2016
NICE draft guidance does not recommend Nexavar® (sorafenib) for the treatment of patients with advanced hepatocellular carcinoma who have failed or are unsuitable for surgical or loco-regional therapies

The National Institute for Health and Care Excellence (NICE) has released an Appraisal Consultation Document (ACD) with draft guidance not recommending Nexavar® (sorafenib) for the treatment of patients with advanced hepatocellular carcinoma (HCC) who have failed or are unsuitable for surgical or loco-regional therapies.1

August 12, 2016
National Institute for Health and Care Excellence publishes negative draft recommendation for brentuximab vedotin within appraisal consultation document

Takeda UK Ltd has announced that brentuximab vedotin (Adcetris®), a medicine that has rapidly become standard of care for patients with relapsed/refractory Hodgkin’s lymphoma (R/R HL),1 has received a negative recommendation within draft guidance from the National Institute for Health and Care Excellence (NICE).2

July 4, 2016
Recommendation comes 36 months after NICE review was first announced

The National Institute for Health and Care Excellence (NICE) has recommended Ferring’s FIRMAGON® (degarelix) for a group of men with advanced hormone-dependent prostate cancer – those with spinal metastases.

This announcement comes after a review process lasting over three years, and follows NICE’s most recent draft Appraisal Consultation Document published in June 2015, which recommended against the use of FIRMAGON® within its marketing authorisation for treating advanced hormone-dependent prostate cancer.

April 28, 2016
In guidance published this week NICE has recommended new heart failure drug sacubitril valsartan (Entresto, Novartis), the first drug of its kind, as an option for some people with heart failure

The guidance recommends the £3 per day treatment for this life-threatening condition in over 100,000 people with moderate to very severe symptoms whose heart is only able to pump a reduced amount of oxygenated blood around the body (known as a reduced ejection fraction), and whose heart failure is not controlled by the commonly used drugs, ACE inhibitors or ARBs.

September 4, 2015
NICE recommends RoActemra® (tocilizumab) as monotherapy for treatment of severe rheumatoid arthritis

As many as 20,000 patients in England and Wales with severe rheumatoid arthritis (RA) could soon benefit from RoActemra monotherapy, after the National Institute for Health and Care Excellence (NICE) issued a positive Final Appraisal Determination (FAD), recommending the medicine for use on the NHS.

September 3, 2015
Pfizer welcomes the decision from the National Institute for Health and Care Excellence (NICE) to support continued access to biologic disease-modifying anti-rheumatic drugs

Pfizer welcomes the decision from the National Institute for Health and Care Excellence (NICE) to support continued access to biologic disease-modifying anti-rheumatic drugs (DMARDs) such as Enbrel® (etanercept) for patients with severe rheumatoid arthritis (RA) in England and Wales. (1)

The Final Appraisal Determination (FAD) issued by NICE follows a technology appraisal reviewing the most commonly prescribed biologic DMARDs for the treatment of the condition.
 

February 25, 2015
New guidance has been released by the National Institute for Health and Care Excellence (NICE) recommending Olympus Medical’s transurethral resection in saline (TURis) system for use in surgery to reduce the size of enlarged prostate glands in men. NICE published the guidance in light of the potential it offers NHS hospitals to realise substantial cost savings of £285–375 per patient whilst also improving patient outcomes. (1)

New guidance has been released by the National Institute for Health and Care Excellence (NICE) recommending Olympus Medical’s transurethral resection in saline (TURis) system for use in surgery to reduce the size of enlarged prostate glands in men. NICE published the guidance in light of the potential it offers NHS hospitals to realise substantial cost savings of £285–375 per patient whilst also improving patient outcomes. (1)

 

February 15, 2010
Today, Nice releases guidelines on treatment for type 2 diabetes.

Today, Nice releases guidelines on treatment for type 2 diabetes.
 
Patients now have the option to recieve cost effective treatment  by combining once-daily liraglutide with two oral anti-diabetic tablets.

The recommendation is for patients with a Body Mass Index (BMI) above 35 however, it may be used in some patients with a BMI below 35.

Further information will be released by NICE in support of this new treatment option.